Cost-Effectiveness Analysis of Interventional Liver-Directed Therapies for a Single, Small Hepatocellular Carcinoma in Liver Transplant Candidates

被引:3
|
作者
Wu, Xiao [1 ]
Heller, Michael [1 ]
Kwong, Allison [3 ]
Fidelman, Nicholas [1 ]
Mehta, Neil [2 ]
机构
[1] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Gen Hepatol & Liver Transplantat, 513 Parnassus Ave,Room S-357, San Francisco, CA 94143 USA
[3] Stanford Univ, Dept Gastroenterol & Hepatol, San Francisco, CA USA
关键词
TRANSARTERIAL CHEMOEMBOLIZATION; RADIOFREQUENCY ABLATION; TRENDS; RESECTION; OUTCOMES; SCORE; Y-90;
D O I
10.1016/j.jvir.2023.02.016
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To assess the cost effectiveness of 3 main locoregional therapies (LRTs) (transarterial chemoembolization [TACE], transarterial radioembolization [TARE], and percutaneous ablation) as bridging therapy.Materials and Methods: A cost-effectiveness analysis was performed comparing the 3 LRTs for patients with a single hepatocellular carcinoma (HCC) with a diameter of 3 cm or less over a 5-year time horizon from a payer's perspective. The clinical courses, including transplantation, decompensation resulting in delisting, and the need for a second LRT, were based on data from the United Network for Organ Sharing (2016-2019). Costs and effectiveness were measured in U.S. dollars and quality-adjusted life-years, respectively. Probabilistic and deterministic sensitivity analyses were performed. Results: A total of 2,594, 1,576, and 903 patients underwent TACE, ablation, and TARE, respectively. Ablation was the dominant strategy, with the lowest expected cost and highest effectiveness. The probabilistic sensitivity analysis demon-strated that ablation was the most cost-effective strategy in 93.9% of simulations. A subgroup analysis was performed for different wait times, with ablation remaining the most cost-effective strategy. The sensitivity analysis showed that ablation was most effective if the risk of waitlist dropout was less than 2.00% and the rate of transplantation was more than 15.1% quarterly. TARE was most effective if the risk of dropout was less than 1.19% and the rate of transplantation was more than 24.0%. TACE was most effective if the risk of dropout was less than 1.01% and the rate of transplantation was more than 45.7%. Ablation remained the most cost-effective modality until its procedural cost was more than $34,843.Conclusions: Ablation is the most cost-effective bridging strategy for patients with a single, small (& LE;3 cm) HCC prior to liver transplantation. The conclusion remained robust in multiple sensitivity analyses.
引用
收藏
页码:1237 / 1246.e3
页数:13
相关论文
共 50 条
  • [21] Clinical Outcomes After Interventional Radiology Liver Directed Therapies for Hepatocellular Carcinoma in Pre-Liver Transplant Patients: A Retrospective Study
    Gonzalez, Adalberto
    Kassner, Samantha
    Doshi, Mehul
    Al-Khallouf, Kawtar
    Stadtlander, Kevin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S557 - S558
  • [22] Analysis of liver-directed therapies in US cancer patients
    Alese, O. B.
    Kim, S.
    Chen, Z.
    Ramalingam, S. S.
    Owonikoko, T. K.
    El-Rayes, B. F.
    CURRENT ONCOLOGY, 2015, 22 (06) : E457 - E461
  • [23] Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC)
    Viveiros, Pedro
    Riaz, Ahsun
    Lewandowski, Robert J.
    Mahalingam, Devalingam
    CANCERS, 2019, 11 (08)
  • [24] Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies
    Huber, Timothy C.
    Bochnakova, Teodora
    Koethe, Yilun
    Park, Brian
    Farsad, Khashayar
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2021, 8 : 1181 - 1193
  • [25] Cost-effectiveness of screening for recurrent hepatocellular carcinoma after liver transplantation
    Ladabaum, Uri
    Cheng, Shan L.
    Yao, Francis Y.
    Roberts, John P.
    CLINICAL TRANSPLANTATION, 2011, 25 (02) : 283 - 291
  • [26] Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma
    Salazar, James
    Saxena, Varun
    Kahn, James G.
    Roberts, John P.
    Mehta, Neil
    Volk, Michael
    Lai, Jennifer C.
    TRANSPLANTATION, 2017, 101 (05) : 1001 - 1008
  • [27] Liver-Directed Combined Radiotherapy for Downstaging of the Milan Advanced Hepatocellular Carcinoma Converting to Liver Transplantation
    Kim, Y. T.
    Lee, J. G.
    Joo, D. J.
    Kim, D. Y.
    Seong, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E308 - E308
  • [28] Liver transplant candidates with hepatocellular carcinoma: A retrospective analysis of their evaluation and outcome.
    Yamashiki, N
    Kato, T
    Reddy, KR
    Sobhonslidsuk, A
    Nishida, S
    Levi, D
    Schiff, ER
    Tzakis, AG
    HEPATOLOGY, 2001, 34 (04) : 663A - 663A
  • [29] Cost-Effectiveness of Local Therapies for Inoperable, Localized Hepatocellular Carcinoma
    Pollom, E.
    Lee, K.
    Durkee, B. Y.
    Grade, M.
    Mokhtari, D.
    Weeks, B.
    Feng, M.
    Wahl, D. R.
    Kothary, N.
    Koong, A. C.
    Owens, D.
    Goldhaber-Fiebert, J.
    Chang, D. T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E138 - E138
  • [30] NASH is the Leading Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
    Koh, Jia Hong
    Ng, Cheng Han
    Nah, Benjamin
    Tan, Darren Jun Hao
    Loomba, Rohit
    Huang, Daniel Q.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (01) : 197 - 199